Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

A new study published in JAMA determined that the addition of sugemalimab to chemotherapy enhances overall and ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

Pylori infection, that prevents Gastric Cancer. The best way to diagnose early or advanced gastric cancer is to perform upper GI endoscopy if there are persistent symptoms such as upper abdominal ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For advanced gastric cancer ...

Other symptoms of stomach cancer include unexplained weight loss, black stools containing blood (melaena), nausea and ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

DelveInsight’s, “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ ...

The common phenomenon is often linked to eating and drinking habits but if it persists it could be a sign of something more ...